Jefferies analyst Michael Leuchten assumed coverage of AstraZeneca (AZN) with a Buy rating and 15,000 GBp price target Given what the firm sees as likely outperformance of in-market oncology franchises and the biopharma pipeline, the firm argues that the company’s 2030 $80B sales target is “in sight and is lower risk than perceived.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s New Obesity Drug Study: What Investors Need to Know
- AstraZeneca’s AZD4604: Promising Developments in Asthma Treatment
- Trump Trade: Trump administration prepares new probe into pharma prices
- AstraZeneca, Amgen’s Tezspire approved in EU as add-on therapy
- Trump admin prepares new probe into U.S. pharma prices, FT says